Journal of Clinical & Experimental Pharmacology

NanoBindi- Unified precision therapeutic platform for translating lead candidates to early clinical assets in oncology

Joint Event on 11^th International Conference and Exhibition on Pharmacology and Ethnopharmacology & International Conference on Pharmaceutical Oncology

July 18-19, 2018 | Atlanta, USA

Arkesh Mehta

OncoBindi Therapeutics, USA

Keynote: Clin Exp Pharmacol

Abstract:

To keep up with the pace of change required to deliver a compelling precision therapeutic product and to leverage emerging technologies, we propose a three-tier architecture that provides numerous benefits. It allows a drug developer the opportunity to extend, modularize, and be able to configure their lead compound in a clinical candidate. The architecture shortens time to market and reduces the cost to integrate new clinical functionalities into clinical-outcome focused, patientcentric precision therapeutic. It can also maximize patient adoption through the flexibility it provides when integrating patientfriendly properties into existing drug formulations and therapeutic applications. �??3-tier precision therapeutic architecture is a therapeutic drug-clinical functionality architecture in which the functional process logic, drug release, targeting function and clinical function interface are developed and maintained as independent modules�?�. A �??tier�?� in this case can also be referred to as a �??layer�?�. The three tiers, or layers, involved include: (a) A presentation layer that sends drug molecules to target sites in the form to elicit optimal efficiency. This might leverage clinical functions like targeting, protection from host defense, and ondemand controlled release, etc. (b) A clinical functional layer that uses an fictional fabric layer and processes the business logic for the seamless integration of clinical functionalities. (c) A drug core which is at the heart of the precision therapeurtic. This could be a single drug, acombination drug, immunooncology drugs or CRISPR/Cas system. Here we present outline of NanoBindi-a precision therapeutic development platform that meets all these objectives to turn lead candidates to clinical candidates.

Biography :

Arkesh Mehta is a lifelong entrepreneur with experience up and down the biopharmaceutical spectrum since his first startup more than 15 years ago. Arkesh has co-founded and/or served as CEO or Executive Chairman for a set of leading-edge biotechnology, molecular diagnostics and healthcare IT companies. All of these companies had successful exits including BPI technologies, AT-GC BioPharm, Avanti NanoSciences and CBTEK. Arkesh is an advisor and Board member of several bio and healthcare startups. He has organized, Chaired or participated in number of international panels, including organizing the First NASDAQ panel on Bio-IT. He is a member of Trustees for Sushita Group, a non-profit that fosters entrepreneurship.

E-mail: arkesh.mehta@gmail.com